RxDoctor Payments Data

Darragh Gott

Family · Colorado Springs, CONPI 1194987396

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,562in general payments, 2019–2025

Across 270 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$696
  • Novo Nordisk$676
  • Pfizer$572
  • Lilly USA, LLC$464
  • Amgen$431
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,562 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$27,314
OzempicSemaglutide18$21,969
JardianceEmpagliflozin14$19,758
Tresiba Flextouch U-200Insulin Degludec13$7,240
JanuviaSitagliptin Phosphate12$6,607
BelsomraSuvorexant13$3,650
ProgesteroneProgesterone, Micronized67$2,404
Armour ThyroidThyroid,pork19$1,985
Ipratropium Bromide31$1,672
SynthroidLevothyroxine Sodium11$1,501
Testosterone Cypionate22$934
Np ThyroidThyroid,pork14$869
Gabapentin24$827
Methadone Hcl12$800
Amitriptyline Hcl15$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$464$27,31416 claims
Novo NordiskOzempic$676$21,96918 claims
Boehringer IngelheimJardiance$258$19,75814 claims
MerckJanuvia, Belsomra$16$10,25725 claims
AbbVieArmour Thyroid, Synthroid$1,205$3,48630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →